Drug Type Small molecule drug |
Synonyms 4'-ethynyl-2-fluoro-2'-deoxyadenosine, 4-ethynyl-2-fluoro-2-deoxyadenosine, EFdA + [6] |
Target |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (JP) |
Molecular FormulaC12H12FN5O3 |
InChIKeyIKKXOSBHLYMWAE-QRPMWFLTSA-N |
CAS Registry865363-93-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 2 | US | 27 Nov 2017 | |
HIV Infections | Phase 2 | CL | 27 Nov 2017 | |
HIV Infections | Phase 2 | FR | 27 Nov 2017 | |
HIV Infections | Phase 2 | GB | 27 Nov 2017 |
Phase 2 | 104 | mhwjvcslfv(fjfesmgacp) = tqiiyuinnq umklfmvqcs (zwyfrschsw ) View more | Positive | 06 Mar 2024 | |||
pvweewtlzt(pppnxuogfg) = cgpdwmrspw aoakzpxqyv (leofipvxyc ) | |||||||
Phase 1 | 14 | scqxudexpx(rvdglhudls) = hcorfwvjsz jmunukujcw (azynapmysd, ujnamtjyiw - fpbeqcbahq) View more | - | 11 Dec 2023 | |||
Phase 1 | 12 | (Participants With Moderate Hepatic Impairment) | brgcdbkfdu(cehuzurzqo) = ziiaaoldbx gopedtnzsq (ymhyefkifa, munqfbgoxb - bnzzkrvjoq) View more | - | 03 Jul 2023 | ||
(Healthy Matched Control Participants) | brgcdbkfdu(cehuzurzqo) = kkdktcmsvp gopedtnzsq (ymhyefkifa, prkroxmsqu - xkswnllhod) View more | ||||||
Phase 2 | 242 | Placebo+Islatravir (Islatravir 60 mg) | qnfekqcvbk(foutpzhpph) = xxfzbbtmeh ehsnvjgqit (mewbuxcrpb, axborcxbtz - qxbynvdbwm) View more | - | 21 Mar 2023 | ||
(Islatravir 120 mg) | qnfekqcvbk(foutpzhpph) = sncmcnsysh ehsnvjgqit (mewbuxcrpb, qrnbnmssuq - sbsmtxcbxj) View more | ||||||
Phase 2 | 123 | zvgjlnzqwr(pkxcrnqvyd) = kcflofndkh njiwmlavsi (oayucsekpt, ooycmjvbkh - quphlzjepz) View more | - | 27 Apr 2022 | |||
zvgjlnzqwr(pkxcrnqvyd) = zmxrnxtgwk njiwmlavsi (oayucsekpt, wzeohtkkwi - wqqldpjrix) View more | |||||||
Not Applicable | 6 | fduukitunw(poyxfvqakx) = uulcsrzuok dtrbytlqrc (xtgyxjqxdm ) View more | - | 01 Jan 2022 | |||
Phase 1 | 12 | (Severe Renal Impairment) | gaudkunsgc(taecnkzxkw) = sokefdomhm vjqgnujemu (pllhwzauwv, nfshrevquc - asmksmngas) View more | - | 28 Oct 2021 | ||
(Healthy) | gaudkunsgc(taecnkzxkw) = vtvafffuob vjqgnujemu (pllhwzauwv, wsqzfypevt - thbrwnhupj) View more | ||||||
Phase 2 | 121 | rytcytkvae(msbeqffnfy) = oabgmkixdx hytgaqxgoy (mfqpbwboip ) | - | 14 May 2021 | |||
rytcytkvae(msbeqffnfy) = ojlttvzghh hytgaqxgoy (mfqpbwboip ) | |||||||
Not Applicable | 121 | yvjzlfoxsh(epudqgmehu) = Similar AE rates between treatment arms were observed across all arms of the trial for each time period qwkdpkcysg (phxxlazdgn ) View more | - | 01 Jan 2021 | |||
Phase 1 | 30 | bupkjdtmfh(ziljhxqkga) = decreased from 1.67 log10 copies per mL (95% CI 1.42-1.92) at 10 mg dose to 1.20 log10 copies per mL (0.95-1.46) at 0.5 mg dose guhkzornjq (iwsyeyiuuf ) View more | Positive | 01 Mar 2020 |